Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533660 · ClinicalTrials.gov registry record · NA
Alcohol Biosensor Monitoring for Alcoholic Liver Disease
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT03533660 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 33 participants.
The verdict
NCT03533660, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Successful treatment of alcohol associated liver disease (AALD) depends primarily on abstinence from alcohol. The investigators propose a randomized clinical trial of alcohol biosensor monitoring for patients with alcohol associated liver disease to determine if monitoring with feedback on alcohol use patterns reduces alcohol consumption and improves outcomes.
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL Feedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2021-06-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03533660
The ClinicalTrials.gov registry entry for NCT03533660 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enhanced Usual Care is the first listed.
NCT03533660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03533660 about?
NCT03533660 is a clinical study titled "Alcohol Biosensor Monitoring for Alcoholic Liver Disease". Successful treatment of alcohol associated liver disease (AALD) depends primarily on abstinence from alcohol. The investigators propose a randomized clinical trial of alcohol biosensor monitoring for patients with alcohol associated liver disease to determine if monitoring with feedback on alcohol u...
What is the current status of trial NCT03533660?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2018-09-13. Estimated completion is 2021-06-28.
What interventions are being tested in trial NCT03533660?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Feedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT03533660?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.